JP7566923B2 - 抗gitr抗体およびその使用 - Google Patents

抗gitr抗体およびその使用 Download PDF

Info

Publication number
JP7566923B2
JP7566923B2 JP2022552323A JP2022552323A JP7566923B2 JP 7566923 B2 JP7566923 B2 JP 7566923B2 JP 2022552323 A JP2022552323 A JP 2022552323A JP 2022552323 A JP2022552323 A JP 2022552323A JP 7566923 B2 JP7566923 B2 JP 7566923B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022552323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506593A5 (cg-RX-API-DMAC7.html
JP2023506593A (ja
Inventor
ロバート バブ,
ドリュー ダジェオン,
ユー ファン,
ロザリン モルデン,
ウィリアム オルソン,
マシュー スリーマン,
ディミトリス スココス,
ベイ ワン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023506593A publication Critical patent/JP2023506593A/ja
Publication of JP2023506593A5 publication Critical patent/JP2023506593A5/ja
Priority to JP2024078761A priority Critical patent/JP2024097985A/ja
Application granted granted Critical
Publication of JP7566923B2 publication Critical patent/JP7566923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022552323A 2020-03-06 2021-03-05 抗gitr抗体およびその使用 Active JP7566923B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024078761A JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986494P 2020-03-06 2020-03-06
US62/986,494 2020-03-06
PCT/US2021/021109 WO2021178814A1 (en) 2020-03-06 2021-03-05 Anti-gitr antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024078761A Division JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2023506593A JP2023506593A (ja) 2023-02-16
JP2023506593A5 JP2023506593A5 (cg-RX-API-DMAC7.html) 2024-03-05
JP7566923B2 true JP7566923B2 (ja) 2024-10-15

Family

ID=75223517

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552323A Active JP7566923B2 (ja) 2020-03-06 2021-03-05 抗gitr抗体およびその使用
JP2024078761A Withdrawn JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024078761A Withdrawn JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Country Status (14)

Country Link
US (2) US11787867B2 (cg-RX-API-DMAC7.html)
EP (1) EP4114859A1 (cg-RX-API-DMAC7.html)
JP (2) JP7566923B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220151172A (cg-RX-API-DMAC7.html)
CN (1) CN115244084A (cg-RX-API-DMAC7.html)
AU (1) AU2021232041A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017156A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168173A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002404A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022012467A2 (cg-RX-API-DMAC7.html)
IL (1) IL296043A (cg-RX-API-DMAC7.html)
MX (2) MX2022010910A (cg-RX-API-DMAC7.html)
PH (1) PH12022552295A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021178814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545265A (ja) * 2019-08-20 2022-10-26 ニューリタス リミテッド 筋萎縮を治療するためのペプチド
MX2022010910A (es) 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527919A (ja) 2015-08-14 2018-09-27 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗tigit抗体
JP2019521098A (ja) 2016-06-10 2019-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗gitr抗体およびその使用
JP2019532619A (ja) 2016-08-02 2019-11-14 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. ヒトctla−4に対する抗体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO1999025834A1 (en) 1997-11-18 1999-05-27 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Th2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
MX2018006072A (es) * 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
KR102209364B1 (ko) * 2016-12-09 2021-02-01 리제너론 파아마슈티컬스, 인크. T 세포 수용체를 시퀀싱하기 위한 시스템 및 방법 및 이의 용도
MX2022010910A (es) 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527919A (ja) 2015-08-14 2018-09-27 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗tigit抗体
JP2019521098A (ja) 2016-06-10 2019-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗gitr抗体およびその使用
JP2019532619A (ja) 2016-08-02 2019-11-14 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. ヒトctla−4に対する抗体

Also Published As

Publication number Publication date
CN115244084A (zh) 2022-10-25
WO2021178814A1 (en) 2021-09-10
PH12022552295A1 (en) 2024-01-22
JP2023506593A (ja) 2023-02-16
JP2024097985A (ja) 2024-07-19
AU2021232041A1 (en) 2022-09-08
CO2022012467A2 (es) 2022-09-20
US20240076396A1 (en) 2024-03-07
CA3168173A1 (en) 2021-09-10
MX2022010910A (es) 2022-10-07
KR20220151172A (ko) 2022-11-14
EP4114859A1 (en) 2023-01-11
BR112022017156A2 (pt) 2022-11-08
US11787867B2 (en) 2023-10-17
IL296043A (en) 2022-10-01
CL2022002404A1 (es) 2023-03-10
AU2021232041A9 (en) 2023-06-29
US12331127B2 (en) 2025-06-17
US20210340267A1 (en) 2021-11-04
MX2023012739A (es) 2023-11-09

Similar Documents

Publication Publication Date Title
US20240166740A1 (en) Anti-lag3 antibodies and uses thereof
JP7174009B2 (ja) Pd-1に対するヒト抗体
US20230042324A1 (en) Anti-gitr antibodies and uses thereof
AU2015229591A1 (en) Anti-EGFRvlll antibodies and uses thereof
JP2021520201A (ja) 抗cd27抗体およびその使用
JP2024097985A (ja) 抗gitr抗体およびその使用
JP7743313B2 (ja) Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
EA047743B1 (ru) Антитела к gitr и варианты их применения
EA048356B1 (ru) МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28
EA050284B1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
EA051787B1 (ru) Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения
EA039583B1 (ru) Антитела против gitr и их применения
NZ788539A (en) Anti-gitr antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240226

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241002

R150 Certificate of patent or registration of utility model

Ref document number: 7566923

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150